Michael J. Reardon

Michael J. Reardon

Auto-generated profile, based on publicly available information

Michael J. Reardon

Department of Cardiovascular Surgery, Houston Methodist Hospital, 6565 Fannin St, Houston, TX, 77030, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in JACC
Verified
Journal Article
Closed access
MRMichael J. Reardon
Michael J. Reardon
DADavid H. Adams
David H. Adams
NKNeal S. Kleiman
Neal S. Kleiman
SYSteven J. Yakubov
Steven J. Yakubov
JCJoseph S. Coselli
Joseph S. Coselli
JPJeffrey J. Popma
Jeffrey J. Popma

1 February 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
BRBasel Ramlawi
Basel Ramlawi
MLMonika J. Leja
Monika J. Leja
WSWalid K. Abu Saleh
Walid K. Abu Saleh
OJOdeaa Al Jabbari
Odeaa Al Jabbari
RBRobert Benjamin
Robert Benjamin
MRMichael J. Reardon
Michael J. Reardon

1 February 2023 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
DODaniel O’hAir
Daniel O’hAir
SYSteven J. Yakubov
Steven J. Yakubov
KGKendra J. Grubb
Kendra J. Grubb
JOJae K. Oh
Jae K. Oh
SISaki Ito
Saki Ito
MRMichael J. Reardon
Michael J. Reardon
Importance: The frequency and clinical importance of structural valve deterioration (SVD) in patients undergoing self-expanding transcatheter aortic valve implantation (TAVI) or surgery is poorly understood.Objective: To evaluate the 5-year incidence, clinical outcomes, and predictors of hemodynamic SVD in patients undergoing self-expanding TAVI or surgery.Design, Setting, and Participants: This post hoc analysis pooled data from the CoreValve US High Risk Pivotal (n = 615) and SURTAVI (n = 1484) randomized clinical trials (RCTs); it was supplemented by the CoreValve Extreme Risk Pivotal trial (n = 485) and CoreValve Continued Access Study (n = 2178). Patients with severe aortic valve stenosis deemed to be at intermediate or increased risk of 30-day surgical mortality were included. Data were collected from December 2010 to June 2016, and data were analyzed from December 2021 to October 2022.Interventions: Patients were randomized to self-expanding TAVI or surgery in the RCTs or underwent self-expanding TAVI for clinical indications in the nonrandomized studies.Main Outcomes and Measures: The primary end point was the incidence of SVD through 5 years (from the RCTs). Factors associated with SVD and its association with clinical outcomes were evaluated for the pooled RCT and non-RCT population. SVD was defined as (1) an increase in mean gradient of 10 mm Hg or greater from discharge or at 30 days to last echocardiography with a final mean gradient of 20 mm Hg or greater or (2) new-onset moderate or severe intraprosthetic aortic regurgitation or an increase of 1 grade or more.Results: Of 4762 included patients, 2605 (54.7%) were male, and the mean (SD) age was 82.1 (7.4) years. A total of 2099 RCT patients, including 1128 who received TAVI and 971 who received surgery, and 2663 non-RCT patients who received TAVI were included. The cumulative incidence of SVD treating death as a competing risk was lower in patients undergoing TAVI than surgery (TAVI, 2.20%; surgery, 4.38%; hazard ratio [HR], 0.46; 95% CI, 0.27-0.78; P = .004). This lower risk was most pronounced in patients with smaller annuli (23 mm diameter or smaller; TAVI, 1.32%; surgery, 5.84%; HR, 0.21; 95% CI, 0.06-0.73; P = .02). SVD was associated with increased 5-year all-cause mortality (HR, 2.03; 95% CI, 1.46-2.82; P < .001), cardiovascular mortality (HR, 1.86; 95% CI, 1.20-2.90; P = .006), and valve disease or worsening heart failure hospitalizations (HR, 2.17; 95% CI, 1.23-3.84; P = .008). Predictors of SVD were developed from multivariate analysis.Conclusions and Relevance: This study found a lower rate of SVD in patients undergoing self-expanding TAVI vs surgery at 5 years. Doppler echocardiography was a valuable tool to detect SVD, which was associated with worse clinical outcomes.Trial Registration: ClinicalTrials.gov Identifiers: NCT01240902, NCT01586910, and NCT01531374

1 July 2017 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
WSWalid K. Abu Saleh
Walid K. Abu Saleh
BRBasel Ramlawi
Basel Ramlawi
OSOz M. Shapira
Oz M. Shapira
OJOdeaa Al Jabbari
Odeaa Al Jabbari
VRVinod Ravi
Vinod Ravi
MRMichael J. Reardon
Michael J. Reardon

20 January 2023 in European Heart Journal
Verified
Journal Article
Closed access
YAYousif Ahmad
Yousif Ahmad
JHJames P Howard
James P Howard
AAAhran D Arnold
Ahran D Arnold
MMMahesh V Madhavan
Mahesh V Madhavan
CCChristopher M Cook
Christopher M Cook
MLMartin B Leon
Martin B Leon
Aims: Additional randomized clinical trial (RCT) data comparing transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) is available, including longer term follow-up. A meta-analysis comparing TAVI to SAVR was performed. A pragmatic risk classification was applied, partitioning lower-risk and higher-risk patients.Methods and results: The main endpoints were death, strokes, and the composite of death or disabling stroke, occurring at 1 year (early) or after 1 year (later). A random-effects meta-analysis was performed. Eight RCTs with 8698 patients were included. In lower-risk patients, at 1 year, the risk of death was lower after TAVI compared with SAVR [relative risk (RR) 0.67; 95% confidence interval (CI) 0.47 to 0.96, P = 0.031], as was death or disabling stroke (RR 0.68; 95% CI 0.50 to 0.92, P = 0.014). There were no differences in strokes. After 1 year, in lower-risk patients, there were no significant differences in all main outcomes. In higher-risk patients, there were no significant differences in main outcomes. New-onset atrial fibrillation, major bleeding, and acute kidney injury occurred less after TAVI; new pacemakers, vascular complications, and paravalvular leak occurred more after TAVI.Conclusion: In lower-risk patients, there was an early mortality reduction with TAVI, but no differences after later follow-up. There was also an early reduction in the composite of death or disabling stroke, with no difference at later follow-up. There were no significant differences for higher-risk patients. Informed therapy decisions may be more dependent on the temporality of events or secondary endpoints than the long-term occurrence of main clinical outcomes.

1 November 2016 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
MRMichael J. Reardon
Michael J. Reardon
NKNeal S. Kleiman
Neal S. Kleiman
DADavid H. Adams
David H. Adams
SYSteven J. Yakubov
Steven J. Yakubov
JCJoseph S. Coselli
Joseph S. Coselli
JPJeffrey J. Popma
Jeffrey J. Popma
Transcatheter aortic valve replacement (TAVR) with balloon-expandable and self-expanding valves is now an accepted alternative to surgical aortic valve replacement (SAVR) in the treatment of symptomatic severe aortic stenosis in patients at increased risk for surgery.1,2 The Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM), used alone or in part to select patients for TAVR, has decreased over time since the first randomized trial of balloon-expandable TAVR with a study mean of 11.6%,3 to the 2016 study in intermediate-risk patients with a mean of 5.8%.4 Transcatheter aortic valve replacement using a self-expanding valve (CoreValve bioprosthesis; Medtronic) has shown superior survival compared with SAVR at 1 year5 and 2 years6 in patients with a mean STS PROM score of 7.4%.